Skip to content
What Causes What
MECHANISM− DECREASES

GLP-1 receptor agonist → Obstructive sleep apnea

Higher GLP-1 receptor agonist decreases Obstructive sleep apnea.

In two 52-week trials of adults with obesity and moderate-to-severe sleep apnea, weekly tirzepatide cut the apnea-hypopnea index by about 20 to 24 events per hour versus placebo (Malhotra, Grunstein, Fietze 2024).

Randomized trial · Moderate · N=469

Supported by an experiment or a tightly identified design. Read the caveats.

Mechanism

Tirzepatide copies two gut hormones, GIP and GLP-1. They slow the stomach, raise insulin when glucose is high, and cut appetite. Fat in the tongue and neck then falls as weight falls, and the airway stays open more of the night. Malhotra, Grunstein, Fietze and colleagues (2024) ran two phase 3 trials in adults with obesity and an apnea-hypopnea index of 15 or more. Trial 1 enrolled people not on a breathing machine. Trial 2 enrolled people who were. Assignment was the highest tolerated weekly tirzepatide, 10 or 15 mg, or placebo, for 52 weeks. The primary end point was change in events per hour of sleep. In trial 1 the treatment difference was -20.0 events per hour (95 percent CI -25.8 to -14.2). In trial 2 it was -23.8 (-29.6 to -17.9). full_text. A later look at the same trials (Malhotra 2025) found that a home sleep test moved as early as week 4, but the gap versus placebo was not clear until week 20, and the size of the apnea change tracked the weight that was lost. full_text. Falcon, Xie, Redline and colleagues (2026) split the same file by age, sex, starting AHI, BMI, and neck size. The AHI fall showed up in each slice. abstract_only.

Caveats

Someone was assigned a pen, so the stamp is an RCT stamp. The two trials are one program in people with obesity and moderate-to-severe apnea. They do not speak for lean people or mild snoring. A large share of the apnea change tracks weight. The authors have not isolated a direct airway effect. Gut side effects were the usual reason people left. Trial 2 took people off their breathing machine before the sleep tests. Did not hang Kanu 2025 (p-pmid-40774158): sleep and quality-of-life scores in the same trials, not the event count. Did not hang the 2026 oral semaglutide liver file (p-pmid-41066034): the title is liver, not apnea. Did not hang the claims-database semaglutide association (p-pmid-41915556): new-onset billing codes, not an assigned AHI. Did not hang the Annals journal-club note or the hypoxic-burden commentary. This page is a journal entry. It is not medical advice and not a reason to start or stop a drug.

Effect

qualitative. SURMOUNT-OSA AHI ETD -20.0/h trial 1 (CI -25.8 to -14.2), -23.8/h trial 2 (CI -29.6 to -17.9). N=469. 52 wk. Malhotra 2024.

Nodes

Lifestyle & environmentGLP-1 receptor agonistBiology & endocrinologyObstructive sleep apnea

Named confounders

Cite this page

What Causes What. “GLP-1 receptor agonist → Obstructive sleep apnea.” https://whatcauseswhat.org/edges/e-glp1-osa (atlas updated 2026-09-02).

https://whatcauseswhat.org/edges/e-glp1-osa

Papers